OmniAb (OABI) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and OmniAb published the results on October 30, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• OmniAb reports in thousands; figures here are in millions. License and milestone revenue swings with partners' milestones: OmniAb recognized no milestones in Q3 2026 or Q3 2025, while nine-month milestone revenue rose by $18.3 million.
• Q1 2026 amortization of intangibles included a $2.9 million non-cash impairment for discontinued legacy small-molecule ion channel programs.

Source: OmniAb Q3 2026 results, October 30, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How OmniAb splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• OmniAb's License and milestone revenue revenue was $0.1 million in Q3 2026, down 84% from $0.6 million in Q3 2025, 3% of total revenue.
• OmniAb's Service revenue revenue was $2.8 million in Q3 2026, up 139% from $1.2 million in Q3 2025, 71% of total revenue.
• OmniAb's xPloration revenue revenue was $0.7 million in Q3 2026, up 850% from $0.1 million in Q3 2025, 18% of total revenue.
• OmniAb's Royalty revenue revenue was $0.4 million in Q3 2026, down 2% from $0.4 million in Q3 2025, 9% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, OmniAb said:

“OmniAb revises 2026 financial guidance and now expects revenue to be in the range of $35 million to $39 million, versus $32 million to $36 million previously, and costs and operating expenses to be in the range of $83 million to $87 million, versus $84 million to $88 million previously.”

“Cash costs and operating expenses are expected to be in the range of $50 million to $54 million, versus $51 million to $55 million previously”

“The Company now expects to end the year with cash and cash equivalents in the range of $53 million to $57 million, versus $49 million to $53 million previously.”

“OmniAb expects xPloration revenue in 2026 to be between $2 million and $3 million and expects xPloration revenue to double in 2027 and to double again in 2028.”

Source: OmniAb Q3 2026 release (Form 8-K, Exhibit 99.1), Oct 30, 2026.

This is the company's own guidance as of Oct 30, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the OABI forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue and net loss per share, basic and diluted, each as first reported in that quarter's release.

We do not hold a confirmed date for OmniAb's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 30, 2026

OmniAb licenses antibody discovery technology to drug developers and earns license fees, milestones on partnered programs, service revenue from research work, royalties, and sales of its xPloration screening platform. Total revenue was $4.0 million in Q3 2026, against $2.2 million a year earlier. (OmniAb Q3 2026 release, Oct 30, 2026)

Service revenue was the largest line at $2.8 million, up from $1.2 million, on more work on antibody and ion channel programs. xPloration revenue rose to $703 thousand from $74 thousand on higher instrument and consumable sales. License and milestone revenue fell to $100 thousand from $616 thousand on lower license revenue, and royalty revenue was $355 thousand against $361 thousand. (OmniAb Q3 2026 release, Oct 30, 2026; OmniAb Form 10-Q, Q3 2026, Oct 30, 2026)

Milestones make OmniAb's revenue lumpy. No milestones were recognized in Q3 2026 or Q3 2025, but over the first nine months of 2026 license and milestone revenue was $21.6 million, against $3.9 million, mainly from an $18.3 million increase in milestone revenue. Total nine-month revenue was $31.8 million, against $10.3 million. (OmniAb Form 10-Q, Q3 2026, Oct 30, 2026; OmniAb Q3 2026 release, Oct 30, 2026)

At September 30, 2026 OmniAb had 111 active partners and 433 active programs, 34 of them OmniAb-derived clinical and commercial programs. In the quarter it signed a collaboration with Eli Lilly for a new ion channel program, with an up-front payment and up to $370 million in milestone payments plus tiered royalties. Deferred revenue rose to $5.2 million current and $9.7 million long-term, from $3.2 million and nil at the end of 2025. (OmniAb Q3 2026 release, Oct 30, 2026)

OmniAb reports GAAP EPS only. Its net loss was $15.7 million, or $0.12 per share, in Q3 2026, against $16.5 million, or $0.14, a year earlier. Total costs and operating expenses were $20.4 million in both quarters: research and development fell to $9.6 million from $10.4 million while general and administrative rose to $7.2 million from $6.8 million. (OmniAb Q3 2026 release, Oct 30, 2026)

Much of the cost base is non-cash. Amortization of intangibles was $3.1 million and share-based compensation $3.1 million. OmniAb's non-GAAP measure, cash costs and operating expenses, removes those and depreciation: $13.7 million in Q3 2026, against $12.3 million. (OmniAb Q3 2026 release, Oct 30, 2026)

Weighted-average shares were 129,295 thousand, against 114,726 thousand a year earlier, while 145,855,652 shares were issued and outstanding at September 30, 2026. The gap is mostly 16,292,542 earnout shares from OmniAb's business combination, which are excluded from the share count until price-based vesting conditions are met. OmniAb expects a full-year 2026 effective tax rate of approximately 0%. (OmniAb Q3 2026 release, Oct 30, 2026; OmniAb Form 10-Q, Q3 2026, Oct 30, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

OmniAb gives full-year guidance in its release and raised it again in Q3 2026. It now expects 2026 revenue of $35 million to $39 million, up from $32 million to $36 million, costs and operating expenses of $83 million to $87 million, and cash costs and operating expenses of $50 million to $54 million. It expects to end 2026 with $53 million to $57 million of cash and cash equivalents, against $64.2 million of cash, cash equivalents and short-term investments at September 30, 2026. (OmniAb Q3 2026 release, Oct 30, 2026)

OmniAb opened xPloration sales to all customers in October 2026, beyond the Partner Access Program launched in 2025. It expects xPloration revenue of $2 million to $3 million in 2026, doubling in 2027 and again in 2028, and puts the market opportunity at more than $500 million. (OmniAb Q3 2026 release, Oct 30, 2026)

A consensus figure is the average of the models published by the analysts who cover OmniAb, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones OmniAb's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning OABI is on is OABI a buy or a sell?, what analysts expect next is on the OABI forecast, and what the company does is on the OmniAb (OABI) stock page.

Every number on this page can be traced to a document OmniAb published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.